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Introduction: 68Ga-radiopharmaceuticals are common in the ﬁeld of Nuclear Medicine to visualize receptor-
mediated processes. In contrast to straightforward labeling procedures for clinical applications, preclinical
in vitro and in vivo applications are hampered for reasons like e.g. volume restriction, activity concentration,
molar activity and osmolality. Therefore, we developed a semi-automatic system speciﬁcally to overcome
these problems. A difﬁculty appeared unexpectedly, as intrinsic trace metals derived from eluate (Zn, Fe and
Cu) are concentrated as well in amounts that inﬂuence radiochemical yield and thus lower molar activity.
Methods: To purify Gallium-68 and to reduce the high elution volume of a 68Ga-generator, a NaCl-basedmethod
using a column containing PS-H+ was implemented in a low volume PEEK system. Inﬂuence on reducing
osmolality, acidity and the amount of PS-H+ resin (15–50 mg) was investigated. [68Ga]Ga was desorbed
from the PS-H+ resin with acidiﬁed 2-5 M NaCl (containing 0.05 M of HCl) and 68Ga-activity was collected.
DOTA-TATE was used as a peptide model. All buffers and additives used for labeling were mixed with Chelex
100 (~1 g/50 mL) for N144 h and eventually ﬁltered using a 0.22 μm ﬁlter (Millipore). Quantiﬁcation of metals
was performed after labeling by HPLC (UV).
Results: Gallium-68 activity could be desorbed from PS-H+ cation column with 3 M NaCl, and N60% (120–
180 MBq) of [68Ga]Ga was collected in b0.3 mL. Taking into account the used amount of 68Ga-eluate, buffer
and other excipients, the overall amount of tracemetal per labeling was b1.5 nmol. DOTA-TATE could be labeled
with [68Ga]Ga with high radiochemical yield, N99% (ITLC), and a radiochemical purity of N95% (HPLC).
Conclusion:With the here described concentration system and metal puriﬁcation technique, a low activity con-
taining 68Ga-generator can be used to label DOTA-peptide in preclinical applicable amounts N60 MBq/nmol
(40–60 MBq/0.1 mL) and within 20 min.
© 2018 . Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
68Ga-radiopharmaceuticals are commonly applied in Nuclear Medi-
cine, e.g. to visualize receptor-mediated processes [1–4]. This resulted in
an increasing interest of the radiopharmaceutical industry to develop
new types of 68Ga-generators, kits and cartridges for radiolabeling
which can be clinically applied [1, 5–10]. In contrast to well established
relative simple labeling procedures for clinical applications [11], pre-
clinical applications are hampered for reasons like volume restriction,
activity concentration (activity per volume, MBq/mL), molar activityPost Ofﬁce Box Number: 2040,
pen access article under the CC BY li(activity per ligand, MBq/nmol), osmolality and metal impurities. High
activity concentration is needed to enable sufﬁcient amount of radio-
pharmaceutical to be injected into small rodents. High molar activity
is important when only small amount of radiopharmaceutical can
injected and imaging have to be performed.
For preclinical applications of 68Ga-radiopharmaceuticals in
mice only low amount of volume can be injected (b200 μL) intrave-
nously (i.v.). Therefore, to perform preclinical studies there is a
need to use high activity containing 68Ga-generators. Since 68Ga-
radiopharmaceuticals are commonly applied into Nuclear Medicine,
many departments use a clinical grade 68Ga-generator. These genera-
tors can only be used for ~9 month time. The reasons for this are the
expiring date of the generator or that the activity is simply too low for
labeling a patient dose. The 68Ga-generator eluate only contains
b300 MBq (~6 mL) [68Ga]Ga, but this activity is still suitable forcense (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Scheme of NaCl based puriﬁcation of 68Ga-generator eluate. A: 6mL of 0.1MHCl for
eluting generator and preconditioning column. B: 10mL syringewith air to empty column
before elution of [68Ga]Ga. C: 1mL syringewith acidiﬁed5MNaCl (containing 0.05MHCl)
for desorption of [68Ga]Ga. Additional valve used to precondition the column without
eluting the generator.
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the activity concentration (i.e. ~500 MBq/mL).
The here described systemwas investigated byusing a clinical grade
68Ga-generator (EZAG), originally with an elution activity of 1110 MBq
[68Ga]Ga (now 200–300 MBq). A semi-automatic puriﬁcation
system was developed speciﬁcally to concentrate [68Ga]Ga into high
volume activities. In contrast to the clinical applied applications in our
clinic of ~35 nmol/150 MBq in 9 mL at ~0.3 osmol (~4.2 MBq/nmol)
for [68Ga]Ga-DOTA-TATE, speciﬁcation for i.v. injection in mice are
0.2 nmol/5 MBq in ≤0.2 mL at ~0.3 osmol (25 MBq/nmol) [12, 13].
A puriﬁcation part is necessary, since high radiolabeling efﬁciencies
for 68Ga-radiopharmaceuticals can only be achieved if other trace
metals are not or only in low amounts present during the radiolabeling
procedure. The reason for this is that the applied peptide model con-
tains the chelator tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) which has the ability to bind also other M2+/3+ metals. For
our concentration system this is especially relevant since it is based on
a cation exchange method. This means that next to [68Ga]Ga, intrinsic
cations, e.g. the trace metals Zn, Fe, and Cu, in the eluate could also be
concentrated to amounts that inﬂuence radiolabeling and thus lower
molar activity of the ﬁnal radiopharmaceutical [14–16]. Therefore, the
work was performed as far as possible metal free, additionally, the ac-
tive removal of metal ions was investigated.
The here described cationic puriﬁcation method is based on a NaCl
technique used for clinical preparation of [68Ga]Ga [17–19]. To desorb
[68Ga]Ga from the resin a 5 M NaCl solution is used. Using these condi-
tions for preclinical application, results in a too high osmolality. To
lower osmolality, the NaCl puriﬁcation technique [18] was adapted by
decreasing the concentration of NaCl and amount of resin used. To our
knowledge there are no publications on these items.
The overall objective of this study was to obtain 68Ga-labeled pep-
tide with a molar activity of 20–30 MBq/nmol within 20 min. The ﬁnal
solution should be isotonic and have a high activity concentration, ap-
plicable for preclinical i.v. injection in mice (b200 μL).
2. Methods and materials
2.1. Materials
All chemicals and solvents were of analytical or pharmaceutical
grade unless otherwise speciﬁed and were obtained from Sigma-
Aldrich. For [68Ga]Ga, a N 9 month old clinical 1110 MBq grade 68Ga-
generator was used (Eckert & Ziegler). DOTA-TATE ([DOTA0,Tyr3]
octreotate, N95% chemical purity) was purchased from BioSynthema.
2.2. Low volume PEEK system
The NaCl based method [18] was implemented in a low volume
PEEK system (tubing 0.03 in.) (Fig. 1). A PEEK Bio-Safe column
(2.1 × 300 mm) including a 2 μm ﬁlter frit with total volume of
173 μL, Triskem) was manually ﬁlled with PS-H+ cation exchange
resin (CHROMAFIX® PS cartridges, pore size 100 Å, particle size
100 μm, 15–50 mg) and connected to a 6-way manual valve
(Inacom instruments). To start puriﬁcation, the valve was switched
to position 2 and the 68Ga-generator was eluted with 6 mL 0.1 M
HCl (A). Gallium-68 was trapped by the PS-H+ cation resin on
the column. To empty the PEEK tubing and the PS-H+ column,
the valve was switched to position 4 and column and tubing
were ﬂushed with 10 mL of air (B). The valve was switched to po-
sition 3 and the content of the syringe (C), 0.5 mL acidiﬁed 5 M
NaCl containing 0.05 M HCl, was used to elute [68Ga]Ga from the
resin. To determine maximum 68Ga-concentration (MBq/μL), 1 mL of
the acidiﬁed NaCl was used to elute [68Ga]Ga in fractions (10 × 0.1 mL)
from the low volume PEEK system containing the PS-H+ cation resin
column. The activity of the obtained eluates was measured in a dose
calibrator (VDC 405, Comecer). To precondition the PS-H+ cation resinfor the next puriﬁcation, the valve was switched to position 1 and 6 mL
0.1 M HCl (A) were pushed through the system.
2.3. Radiolabeling
To obtain high radiolabeling yield, the pH should be around 3.5
[20, 21]. To determine accurately how much buffer is needed, ali-
quots of 100 μL 68Ga-eluate (acidiﬁed 5 M NaCl) were collected by
using the described low volume PEEK system. After decay, pH titra-
tion curves were performed using sodium acetate, sodium formate,
or HEPES as buffer, all were 1.5 Mwith a pH of 5.0 [22]. For the label-
ing, aliquots of 100 μL of 68Ga-eluate (acidiﬁed 5 M NaCl) were ad-
justed to a ﬁnal pH of 3.5 by adding the desired buffer solution.
Using 15 or 50 mg of PS-H+ cation resin and HEPES as buffer,
125 μL and 50 μL are required, respectively. For sodium acetate and
sodium formate only 50 mg of cation PS-H+ resin was applied and
60 μL and 125 μL were needed, respectively, to obtain a pH of 3.5.
DOTA-TATE was used as peptide model. Radiolabeling was started
after addition of DOTA-TATE (up to ~25 MBq/nmol) by heating for
5 min at 80o C [23]. I.e. for a 24 h 68Ga-eluate (120–180 MBq), 4.8–
7.2 μL of DOTA-TATE (1 μmol/mL) was added. After cooling to room
temperature, quality control of [68Ga]Ga-DOTA-TATE was per-
formed. Quality control included radiochemical yield (RCY) of 68Ga
as measured by ITLC-SG [20, 21] and radiochemical purity (RCP) of
[68Ga]Ga-DOTA-TATE as measured by HPLC [24, 25]. RCP is here de-
ﬁned as % of radiotracer that is present in the desired chemical
form. [68Ga]Ga-DOTA-TATE was analyzed with a HPLC system
(Alliance, Waters), containing a UV-detector (W2487 Waters Dual
λ Absorbance Detector). UV absorption was measured at 278 nm. A
Symmetry C18 column (5 mm × 4.6 mm × 250 mm, Waters) was
used with a gradient proﬁle as described earlier [23], mobile phase
0.1% TFA (A) and methanol (B). Radioactivity was monitored with a
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dedicated software (MetorX B·V), connected to the HPLC system.
2.4. Osmolality
If 5 M NaCl solution was used to desorb [68Ga]Ga from the PS-H+
cation resin, after radiolabeling, the reaction mixture had to be diluted
to physiological conditions to achieve the required conditions
(200 pmol/5 MBq [68Ga]Ga-DOTA-TATE in ≤0.2 mL ~0.3 osmol)
which are suitable for i.v. mice injection. To lower the osmolality we
studied the effect of reducing the NaCl concentration and investigated
whether this affects the 68Ga-desorption yields. 2–5 M acidiﬁed NaCl
(1 mL) was used to desorb [68Ga]Ga from PS-H+ resin. Additionally,
the inﬂuence of the amount of PS-H+ resin (15–50 mg) on the
osmolality was studied.
2.5. Trace metal quantiﬁcation
To reducemetal ions (M2+/3+), all buffers and additivesweremixed
with Chelex (1 g/~50 mL) for N144 h, which was removed by ﬁltration
(Millipore, 0.22 μm ﬁlter) before use.
Samples of buffer solutions, 0.1 M HCl solution, and acidiﬁed NaCl,
which was used to eluate [68Ga]Ga, were collected, and trace metals
were quantiﬁed (n= 3). Labeling of DOTA-TATE was performed with
addition of [175Lu]Lu ICP standard with additionally small aliquots
(50 μL) of collected samples. [175Lu]Lu ICP standardwas added to deter-
minewhether labeling conditionswere optimal to obtain incorporation
ofM2+/3+metals. After labeling these sampleswere analyzed byUHPLC
(AcquityH-Class,Waters) (n=3) as described Breemanet al. (for a typ-
ical example see Fig. 2) [26]. Labeling without addition of an aliquot of
sample as described above was considered as reference.
To investigate the inﬂuence of trace metals derived from the de-
scribed low volume PEEK system (Fig. 1.), the PS-H+ resin was rinsed
with N3 M HCl. Trace metal content was determined before and after
rinsing the system by collecting NaCl fractions. Aliquots of collected
NaCl fractions (50 μL) were added and metals were quantiﬁed as de-
scribed above.Fig. 2. UV (278 nm) UHPLC chromatogram of: DOTA-TATE (A) labeled with (B): Zn, (C3. Results
3.1. Low volume PEEK system
After eluting the low volume PEEK system with fractions of in total
1 mL acidiﬁed NaCl, it became clear that only 0.5 mL 5 M acidiﬁed
NaCl was required to desorb [68Ga]Ga. Due to the dead volume of
the system only ~0.3 mL was recovered containing ~60% of the 68Ga-
activity. Puriﬁcation of the eluate resulted in a high activity concen-
tration (400–600 MBq/mL). All The retained volume (dead volume)
was discarded by rinsing the system with 0.1 M HCl. Another reason
for rinsing the system with 0.1 M HCl was preconditioning of the
resin for the next elution of the 68Ga-generator. Calculations of
concentrations of [68Ga]Ga and Zn, but also osmolality are based on
the 0.3 mL of eluate. All elution steps were performed with a ﬂowrate
between 1 and 2mL/min, higher ﬂowrate will result in lower RCY and a
to high pressure within our system.
3.2. Radiolabeling
Aliquots (100 μL) of desorbed [68Ga]Ga in acidiﬁed NaCl were used
to test 3 different buffers. To increase pH to 3.5 only 60 μL of sodium ac-
etate or 125 μL of sodium formate and HEPESwere required (see Fig. 3.)
Labeling performed with a standard molar activity of 25 MBq/nmol
with sodium acetate and sodium formate as buffer resulted in low
RCY (b86%). Best labeling results (N99%) with high reproducibility
(see Fig. 5) were obtained with HEPES as buffer.
4. Osmolality
4.1. NaCl concentration
Reducing NaCl concentration from 5 M down to 2 M resulted in a
decreased desorption of [68Ga]Ga (Fig. 4A). Since reduced NaCl
concentration results in a reduced osmolality of the ﬁnal solution, 3 M
acidiﬁed NaCl, which gave the best desorption results for the less): Fe or (D): Cu. Described method was used to quantify present trace metals [26].
Fig. 3. 68Ga-eluate (acidiﬁed 5 M NaCl) was titrated with sodium acetate, sodium formate and HEPES, respectively.
Choice of buffers was based on Bauwens et al. [22].
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activity could be collected in only 0.3 mL (Fig. 4.B).
4.2. Amount of PS-H+ resin
The RCY decreased by 7% when the amount of PS-H+ cation resin
was reduced by 70%. In addition, the reduction in amount of resin re-
sulted in a reduction of required HEPES buffer to obtain a pH of 3.5.
When reducing the amount of resin from 50mg to 15mg the amount
of HEPES buffer was reduced from 125 μL to 50 μL (Fig. 5). This re-
sulted in a decreased osmolality and a ﬁnal volume reduction of
37%. Radiolabeling performed with 3 M acidiﬁed NaCl using 15 mg
of PS-H+ resin resulted in robust labeling with RCY's of N99% (see
Fig. 6.).
Overall, osmolality of the ﬁnal labeling solution using 3 M NaCl for
68Ga-desorption was 4.5 osmol, to obtain isotonic conditions
(0.3 osmol), a 15× dilution with MilliQ water was required. After dilu-
tion ~5MBq/0.2 nmol in 200 μL [68Ga]Ga-DOTA-TATE could be injected.
5. Trace metal quantiﬁcation
After Chelex 100 treatment of buffers and other additives, trace
metals were reduced from N10 nmol/mL to b1 nmol/mL. DOTA-TATE
could be labeled with [68Ga]Ga at high RCY, N99% (ITLC), and RCP,
N95% (HPLC) (Fig. 5.). After rinsing buffers and additives with ChelexFig. 4. A-B: To investigate maximum 68Ga-concentration (MBq/mL), 0.05MHCl acidiﬁed NaClw
dead volume of the system (~0.2 mL), [68Ga]Ga was collected in ~0.3 mL. A: Desorbed [68Ga]Ga
volume PEEK system.100, the labeling mixture as described above resulted in a total amount
of b1.5 nmol trace metal per labeling.6. Discussion
6.1. Application of low volume PEEK system
When using an 1850 MBq 68Ga-generator, (Eckert & Ziegler, ~60%
RCY) results in 1110 MBq ﬁnal eluate (t = 0). This result, after
radiolabeling and release (1 h), in a maximum activity of ~600 MBq/
6mL. Thismeans that evenwith a new 68Ga-generator, the activity con-
centration is too low for direct preclinical use. To have a continuous ac-
cess to applicable preclinical amounts, the here described low volume
PEEK system is required.
As described in the introduction, in contrast to the clinical applied
speciﬁcations for [68Ga]Ga-DOTA-TATE: 150 MBq 68Ga[Ga] labeled to
~35 nmol of DOTA-TATE in 9 mL at ~0.3 osmol (molar activity:
~4.2 MBq/nmol), speciﬁcations for i.v. injection in mice are: 5 MBq
68Ga[Ga] labeled to 0.2 nmol DOTA-TATE in ≤0.2 mL ~0.3 osmol
(molar activity 25 MBq/nmol). Since uptake of DOTA-TATE is based on
a receptor mediated binding process, a much lower amount
(b0.2 nmol) of DOTA-TATE is required to prevent saturation of the re-
ceptor [12, 27, 28]. Therefore, the clinically applied [68Ga]Ga-DOTA-
TATE procedure could only be used for preclinical application if the
ﬁnal activity is N900 MBq.ith increasingmolarity (2-5M)was used to desorb [68Ga]Ga from PS-H+ resin. Due to the
in % (50 mg of PS-H+) was plotted as ƒ[NaCl]. B: 68Ga-activity proﬁle when using the low
Fig. 5. A-B The effect of the amount of PS-H+ (15–50mg) on the pH of the eluate. A: HEPES-buffer was used to determine the volume required to buffer the eluate to the desired pH (pH:
3.5). B: The effect of the amount of PS-H+ on the RCY of activity in 68Ga-eluate.
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resin can be reused multiple times. After intensive use of the resin (N30
puriﬁcations) lower RCY of the labeling were observed. Therefore, the
PS-H+ resin had to be cleaned by ﬂushing the system with higher con-
centrated HCl (N3 M) or by renewing the resin.
6.2. NaCl concentration/amount of PS-H+ resin
In comparison to Bauwens et al. [22] only small volumes of buffer are
needed to obtain a pH of 3.5. The reasons for this are lower volumes of
eluate and higher concentrations of buffers. Since Bauwens used an
anion puriﬁcation is used it is also likely that small amounts of HCl
end up in ﬁnal solution and inﬂuence the amount of required buffer.
To lower osmolality, the NaCl puriﬁcation technique [18] was adapted
by decreasing the concentration of NaCl and the amount of PS-H+ cat-
ion resin. To our knowledge there are no other publications on these
items. For clinical cationic puriﬁcationmethods using other types of cat-
ion resins, 50–100 mg of resin are regularly used resulting also in high
RCY of [68Ga]Ga [11, 18].
6.3. Trace metal quantiﬁcation
Tominimize addition of trace metal derived from vials or chemicals,
ultra-pure metal free vials, solutions and buffers must be used. AFig. 6. Gallium-68 labeling with high molar activity (20–30 MBq/nmol) was performed
with 68Ga-eluate obtain with either direct elution of the 68Ga-generator or using
described semi-automated system with 50 or 15 mg of PS-H+ resin. Labeling of all three
conditions was performed within 20 min.potential source for intrinsic metals is HCl. Since relative high volumes
of 0.1 M HCl are used to elute the 68Ga-generator and metals (M2+/3+)
are expected to be concentrated on the PS-H+ resin as well, signiﬁcant
amounts of metals can be expected in the ﬁnal labeling solution. This
underlines the importance to use ultra-pure metal free HCl solutions. La-
beling for preclinical use based on receptor mediated processes requires
high molar activity and therefore only nanomoles of molecules/peptides
are used. Under these conditions even small amounts of trace metals
could already inﬂuence radiolabeling. i.e. here performed labeling with
a molar activity of 30 MBq/nmol, starting with a 68Ga-activity of
90 MBq only 3 nmol of peptide is added and 1.5 nmol of trace metal
could already inﬂuence RCY. As shown these conditions resulted in high
RCY. For 68Ga-labeling, Oehlke et al. stated that if metals occupy b80% of
the present molecules to be labeled, no inﬂuence on RCY is expected
[15]. Additionally, labeling kinetics, volume of ﬁnal labeling mixture
could also play a role in achieving high RCY. Moreover, more research
on the resin is required to obtain more information on metal selectivity.
7. Conclusions
With the here described system and metal puriﬁcation technique, a
low activity containing 68Ga-generator can be used to label DOTA-
peptide at 60 MBq/nmol within 20 min. Optimal conditions to achieve
these results are: Elution of 68Ga-generator and other eluent with a
ﬂowrate of 1–2 mL/min, using 15 mg PS-H+ cation resin to absorb
[68Ga]Ga and 3 M of NaCl to desorp [68Ga]Ga and 1.5 M HEPES (pH 5)
as buffer for radiolabelling. DOTA-TATE can be labeled with [68Ga]Ga
at high RCY, N99% (ITLC) and RCP N95% (HPLC). Concentration resulted
in high activity concentration (400–600 MBq/mL). Labeled peptide
(40–60MBq/0.1mL) could be dilutedwithMilliQwater to isotonic con-
ditions (0.3 osmol) in preclinical applicable amounts (~200 μL/mouse).
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